Research and Markets (http://www.researchandmarkets.com/research/3g3vk5/global_psoriatic) has announced the addition of the "Global Psoriatic Arthritis Market 2015-2019" report to their offering.
The global market for psoriatic arthritis is expected to witness moderate growth during the forecast period and factors like the increase in penetration of biologic therapies are expected to augment the prospects for growth in this market.
Additionally, the recent launch of products like Otezla and Stelara is also expected to boost market growth during the forecast period, resulting in its moderate CAGR of nearly 5% by 2019.
In this market research report, The analysts estimate the Americas to account for more than 40% of the total market share by 2019. High market dominion of this region can be attributed to factors such as the increase in public awareness and the growing preference for biologic drugs.
Segmentation by mechanism of action and analysis of: TNF inhibitors, PDE4 inhibitors, & interleukin blockers
The TNF inhibitors aid in suppressing the inflammatory response in the patient's body. These inhibitors are used to manage diseases like rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, and seronegative spondyloarthropathies. Moreover, its ability to use a targeted mechanism to treat most of the inflammatory and autoimmune diseases is primarily responsible for its high market share of almost 80% by 2019.
The mild psoriatic arthritis segment accounts for more than 60% of all the diagnosed cases and is the most common type of psoriatic arthritis in patients across the globe. This condition affects less than four joints in the body and is also known as oligoarticular arthritis.
Competitive landscape and key vendors: Abbvie, Amgen, Janssen Pharmaceuticals
This market is primarily dominated by large vendors due to their extensive product portfolios. The company that manufactures and markets a drug that can treat psoriatic arthritis, and also exhibit a high safety and efficacy profile, is expected to gain a competitive advantage over its rivals during the forecast period.
Leading vendors in this market are
- Abbvie
- Amgen
- Janssen Pharmaceuticals
- Celgene
- UCB
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Product profiles
Part 04: Market research methodology
Part 05: Introduction
Part 06: Disease overview
Part 07: Pipeline portfolio
Part 08: Novel mechanisms targeted by pipeline candidates
Part 09: Market landscape
Part 10: Market segmentation by MoA
Part 11: Market segmentation by type of molecule
Part 12: Market segmentation by severity of disease
Part 13: Market segmentation by route of administration
Part 14: Market segmentation by dosage form
Part 15: Geographical segmentation
Part 16: Market drivers
Part 17: Impact of drivers
Part 18: Market challenges
Part 19: Impact of drivers and challenges
Part 20: Market trends
Part 21: Vendor landscape
Part 22: Key vendor analysis
For more information visit http://www.researchandmarkets.com/research/3g3vk5/global_psoriatic
View source version on businesswire.com: http://www.businesswire.com/news/home/20160114005498/en/